Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30640943.
- Also identified by DOI 10.1371/journal.pone.0210752 and PMC identifier 6331125.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Amyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease with no cure. Currently there are only two ALS drugs approved by the FDA, both with a limited therapeutic effect. In the search for drug candidates for ALS, we studied the effect of known stem cell mobilizing agents (treatment) and antimetabolite 5-fluorouracil (5-FU) (anti-treatment) in SOD1G93A model of ALS. Surprisingly, we found that anti-cancer drug 5-FU increases lifespan, delays the disease onset and improves motor performance in ALS mice. Although we were not able to demonstrate the mechanistic basis of the beneficial 5-FU action in ALS mice, our findings suggest that 5-FU or similar drugs are possible drug candidates for the treatment of motor neuron diseases through drug repurposing.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- Antimetabolites, Antineoplastic
- Fluorouracil
- Superoxide Dismutase